BIOCON

BIOCON

approved_indications FDA Approved Biologics and Pending Applications

Bmab 1000

denosumab
Bmab 1000 Approval Pending

Fulphila®

pegfilgrastim-jmdb
aBL 761075

Hulio®

adalimumab-fkjp
aBL 761154

Insulin-R

insulin human
Insulin-R Approval Pending

Jobevne

bevacizumab-nwgd
aBL 761175

Kirsty

insulin aspart-xjhz
aBL 761188

Ogivri®

trastuzumab-dkst
aBL 761074

Semglee®

insulin glargine-yfgn
aBL 210605 / aBL 761201

Yesafili

aflibercept-jbvf
aBL 761274

Yesintek

ustekinumab-kfce
aBL 761406

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Abevmy (bevacizumab) (Biocon / Viatris) (November-2021)Fulphila® (pegfilgrastim) (Mylan / Biocon) (May-2019) Kirsty (BGP Pharma (Viatris)) (October-2021)Ogivri® (trastuzumab) (Mylan / Biocon) (May-2019)Yesafili (aflibercept) (Biocon) (June-2025)

Biosimilars Approved In The E.U.

Abevmy (bevacizumab) (Biocon / Viatris) (April-2021)Fulphila® (pegfilgrastim) (Mylan / Biocon) (November-2018)Kirsty (previously Kixelle) (insulin aspart) (Viatris / Biocon) (February-2021)Ogivri® (trastuzumab) (Mylan / Biocon) (December-2018)Semglee® (insulin glargine) (Mylan / Biocon) (March-2018)Vevzuo® / Evfraxy® (denosumab) (Biocon) (July-2025)Yesafili (aflibercept) (Biocon) (EU: September-2023; UK: November-2023)

Biosimilars Approved In Australia

Fulphila® (pegfilgrastim) (Alphapharm / Mylan / Biocon) (August-2018)Ogivri® (trastuzumab) (Mylan / Biocon) (December-2018) Semglee® (insulin glargine) (Mylan / Biocon) (March-2018)

Biosimilars Approved In Japan

Insulin glargine BS (insulin glargine) (Biocon / Fujifilm Pharma) (March-2016)

Biosimilars Approved In South Korea

Ogivri® (trastuzumab) (Alvogen Korea) (August-2020)

approved_indications Inter Partes Review Proceedings

GENENTECH CABILLYIPR2016-00710
EYLEA / YESAFILIIPR2024-00201
IPR2024-00298
LANTUS / LANTUS SOLOSTAR / SEMGLEEIPR2017-01526
IPR2017-01528
IPR2018-01670
IPR2018-01675
IPR2018-01676
IPR2018-01677
IPR2018-01678
IPR2018-01679
IPR2018-01680
IPR2018-01682
IPR2018-01684
IPR2018-01696
IPR2019-00122
IPR2019-01657
STELARA / YESINTEKIPR2023-01444

approved_indications U.S. Patent Litigations

EYLEA / YESAFILI1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.)
PROLIA / XGEVA / BMAB 10001:25-cv-13358 (D.N.J.) (transferred from 1:25-cv-11867 (D. Mass.) / MDL 1:25-md-03138 (D.N.J.)

Related News

Thumbnail Image
Fresenius Kabi and Celltrion Launch Prolia® / Xgeva® (denosumab) Biosimilars Conexxence™ / Bomyntra™ and Stoboclo® / Osenvelt®
Robert S. Schwartz, Ph.D.
July 15, 2025
Thumbnail Image
Amgen Files Three New Prolia® / Xgeva® BPCIA Litigations Against Hikma, Shanghai Henlius Biotech, and Biocon’s Proposed Biosimilars
Robert S. Schwartz, Ph.D.
July 3, 2025
Thumbnail Image
Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria®(pegfilgrastim-apgf) / Fylnetra™ (pegfilgrastim-apgf) / Stimufend® (pegfilgrastim-fpgk)
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
June 30, 2025
Thumbnail Image
Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (trastuzumab-dttb) / Trazimera® (trastuzumab-qyyp) / Kanjinti® (trastuzumab-anns) / Hercessi™ (trastuzumab-strf)
April Breyer Menon Frederick C. Millett Corinne E. Atton Robert S. Schwartz, Ph.D.
June 30, 2025
Thumbnail Image
Spotlight On: Humira® (adalimumab) / Amjevita™ (adalimumab-atto) / Cyltezo® (adalimumab-adbm) / Hyrimoz™ (adalimumab-adaz) / Hadlima™ (adalimumab-bwwd) / Abrilada™ (adalimumab-afzb) / Hulio® (adalimumab-fkjp) / Yusimry™ (adalimumab-aqvh) / Idacio® (adalimumab-aacf) / Yuflyma® (adalimumab-aaty) / Simlandi® (adalimumab-ryvk)
April Breyer Menon Corinne E. Atton Joseph K. Yarsky Robert S. Schwartz, Ph.D.
June 30, 2025
Thumbnail Image
Spotlight On: Lantus® / Lantus® SoloSTAR® (insulin glargine recombinant) / Basaglar® (insulin glargine) / Semglee® (insulin glargine) / Rezvoglar™ (insulin glargine-aglr)
April Breyer Menon Damineh Morsali, Ph.D. Corinne E. Atton Robert S. Schwartz, Ph.D.
June 30, 2025
Thumbnail Image
Samsung Bioepis and Formycon’s EYLEA® IPRs Discretionarily Denied Institution Among Wave of Fintiv Denials; Regeneron Files Second BPCIA Lawsuit Against Amgen’s Pavblu™
Robert S. Schwartz, Ph.D.
June 26, 2025
Thumbnail Image
Regeneron and Biocon Settle Litigation over EYLEA® Biosimilar Yesafili™
Robert S. Schwartz, Ph.D.
April 25, 2025
Thumbnail Image
FDA Approves Biocon’s Avastin® Biosimilar Jobevne™ (bevacizumab-nwgd)
Robert S. Schwartz, Ph.D.
April 14, 2025
Thumbnail Image
March Stelara® Biosimilar Launches: Fresenius Kabi’s Otulfi® and Celltrion’s Steqeyma™
Robert S. Schwartz, Ph.D.
March 31, 2025
Thumbnail Image
Stelara® Biosimilars Launch and Licensing Dispute Begins
Robert S. Schwartz, Ph.D.
February 28, 2025
Thumbnail Image
FDA Approves First NovoLog® (insulin aspart) Biosimilar: Sanofi’s Merilog™ / Merilog SoloStar®
Robert S. Schwartz, Ph.D.
February 21, 2025
Thumbnail Image
FDA Accepts EYLEA® Biosimilar Application for Alvotech / Teva’s AVT06
February 21, 2025
Thumbnail Image
Celltrion Files IPR on Regeneron’s EYLEA® Patent
Robert S. Schwartz, Ph.D.
January 22, 2025
Thumbnail Image
Amgen Launches Wezlana™ as the First Stelara® Interchangeable Biosimilar through Optum’s Nuvaila
Robert S. Schwartz, Ph.D.
January 16, 2025
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – November 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
December 12, 2024
Thumbnail Image
Biosimilar Updates: EYLEA® IPR Filings, Herceptin® Biosimilar Hercessi™ Launch, Stelara® Biosimilar Yesintek™ Approval
Robert S. Schwartz, Ph.D.
December 6, 2024
Thumbnail Image
Amgen Launches Pavblu™ as the First EYLEA® Biosimilar in the U.S.
Robert S. Schwartz, Ph.D.
November 14, 2024
Thumbnail Image
Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction
Robert S. Schwartz, Ph.D.
October 24, 2024
Thumbnail Image
Accord BioPharma’s Stelara® Biosimilar Imuldosa™ Approved by FDA
Robert S. Schwartz, Ph.D.
October 18, 2024
Thumbnail Image
Fresenius Kabi and Formycon Announce Approval of Stelara® Biosimilar Otulfi™ in the U.S. and E.U.
Robert S. Schwartz, Ph.D.
October 1, 2024
Thumbnail Image
Preliminary Injunction Against Amgen’s EYLEA® Biosimilar Pavblu™ Denied
Robert S. Schwartz, Ph.D.
September 25, 2024
Thumbnail Image
Regeneron Files BPCIA Complaint Against Sandoz’s EYLEA® Biosimilar Enzeevu™ Following FDA Approval
Robert S. Schwartz, Ph.D.
August 28, 2024
Thumbnail Image
Fifth EYLEA® Biosimilar FDA-Approved: Amgen’s Pavblu™ (aflibercept-ayyh)
Robert S. Schwartz, Ph.D.
August 28, 2024
Thumbnail Image
EYLEA® Biosimilar Updates: Sandoz’s Enzeevu™ (aflibercept-abzv) FDA Approved, Regeneron Dismisses IPR Appeals
Robert S. Schwartz, Ph.D.
August 19, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – July 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
August 10, 2024
Thumbnail Image
FDA Accepts Bio-Thera’s aBLA for Proposed Stelara® (ustekinumab) Interchangeable BAT2206
Robert S. Schwartz, Ph.D.
July 31, 2024
Thumbnail Image
Regeneron Dismisses IPR Appeals and Disclaims EYLEA® (aflibercept) Patents
Robert S. Schwartz, Ph.D.
July 31, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – June 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
July 9, 2024
Thumbnail Image
Preliminary Injunctions Issued Preventing Launch of EYLEA® Biosimilars
Robert S. Schwartz, Ph.D.
July 8, 2024
Thumbnail Image
FDA Approves Three Biosimilars – Ahzantive® (aflibercept-mrbb), Nypozi™ (filgrastim-txid), and Pyzchiva® (ustekinumab-ttwe)
Robert S. Schwartz, Ph.D.
July 3, 2024
Thumbnail Image
Permanent Injunction Issued Preventing Launch of EYLEA® Biosimilar Yesafili™
Robert S. Schwartz, Ph.D.
June 13, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – May 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
June 11, 2024
Thumbnail Image
Regeneron Files Second BPCIA Complaint Against Celltrion’s Proposed EYLEA® Biosimilar CT-P42
Robert S. Schwartz, Ph.D.
May 23, 2024
Thumbnail Image
FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy)
Robert S. Schwartz, Ph.D.
May 21, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – April 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
May 16, 2024
Thumbnail Image
Alvotech and Teva’s Selarsdi™ (ustekinumab-aekn), Biosimilar to Stelara® Approved by FDA
Monica Chou Robert S. Schwartz, Ph.D.
April 23, 2024
Thumbnail Image
EYLEA® Proposed Biosimilar M710 BPCIA Appeals Dismissed for Lack of Jurisdiction
Robert S. Schwartz, Ph.D.
April 17, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – March 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
April 10, 2024
Thumbnail Image
EYLEA® IPR Appeals Filed
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
March 21, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – February 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
March 13, 2024
Thumbnail Image
Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilar
Monica Chou Robert S. Schwartz, Ph.D.
March 6, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – January 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 13, 2024
Thumbnail Image
The PTAB Finds Claims of Two EYLEA® Patents Unpatentable and Regeneron Files its Sixth Complaint Against a Proposed EYLEA® Biosimilar
Damineh Morsali, Ph.D. Robert S. Schwartz
January 31, 2024
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – December 2023
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
January 13, 2024
Thumbnail Image
EYLEA® (aflibercept) IPR and BPCIA Litigation Updates
Damineh Morsali, Ph.D. Robert S. Schwartz
December 15, 2023
Thumbnail Image
Stelara® Biosimilar Updates: IPR Petition Challenging U.S. Patent No. 10,961,307 Filed and SB17 Settlement and Launch Date Announced
Monica Chou Robert S. Schwartz, Ph.D.
December 8, 2023
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – September 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
October 16, 2023
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – July 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 15, 2023
Thumbnail Image
What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?
April Breyer Menon Ha Kung Wong
August 7, 2023
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – February 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 15, 2023
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – January 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
February 9, 2023
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – May 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 7, 2022
Thumbnail Image
Viatris and Biocon Launch First Interchangeable Insulin in the U.S.
April Breyer Menon
November 30, 2021
Thumbnail Image
FDA Approves Boehringer Ingelheim’s Cyltezo® as Interchangeable with Humira®
April Breyer Menon
October 25, 2021
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – July 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 11, 2021
Thumbnail Image
FDA Approves Semglee® (Insulin Glargine) as the First Interchangeable Biosimilar in the U.S.
April Breyer Menon
July 29, 2021
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – April 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 12, 2021
Thumbnail Image
Boehringer Ingelheim Applies for Interchangeability Designation for Cyltezo® (adalimumab-adbm)
April Breyer Menon
April 26, 2021
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – February 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 9, 2021
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – December 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2021
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – August 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 9, 2020
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – March 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
April 8, 2020
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – December 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
January 7, 2020
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – May 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
June 6, 2019
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – April 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
May 7, 2019
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – November 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 11, 2018
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – October 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
November 12, 2018
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – September 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 6, 2018
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – June 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 6, 2018
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – December 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
January 8, 2018
Thumbnail Image
Venable’s BiologicsHQ Monthly Injection – July 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 26, 2017

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha